Dupilumab in Adolescents With Uncontrolled Moderate-To-Severe Atopic Dermatitis: Results From a Phase 2a and Subsequent Open-Label Extension Trial
2019
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI